ADVERTISEMENT

Denosumab Outperforms Zometa in Treating Bone Metastases

A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab not only had fewer bone complications, but they took longer to develop compared with Zometa, reported researchers of a phase 3 study presented Thursday at the San Antonio Breast Cancer Symposium. 

BY MELISSA WEBER
PUBLISHED TUESDAY, DECEMBER 8, 2009
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab not only had fewer bone complications, but they took longer to develop compared with Zometa, reported researchers of a phase 3 study presented Thursday at the San Antonio Breast Cancer Symposium.

For the 2,046 patients given either denosumab or Zometa, denosumab reduced the risk of developing a single skeletal-related event (fracture, radiation, or surgery to the bone, or spinal cord compression) by 18 percent compared with Zometa. For patients who developed multiple skeletal-related events, denosumab reduced the risk by 23 percent. In total, there were 474 skeletal-related events in 30.7 percent of patients in the denosumab group versus 608 events in 36.5 percent of patients on Zometa. 

Plus, denosumab better controlled bone pain, with a median of 88 days until patients experienced moderate or severe pain, compared with 64 days with Zometa.

Both drugs were given every four weeks, and patients were encouraged to take calcium and vitamin D supplements each day. 

Side effects, such as short-term flu-like symptoms, were similar between the two arms, but Zometa caused more side effects overall. The only exception was hypocalcemia (a low level of calcium in the blood), which was more common in the denosumab group. A small percentage of patients in both arms experienced severe jaw damage, known as osteonecrosis of the jaw (2 percent with denosumab and 1.4 percent with Zometa), and kidney problems (4.9 percent and 8.5 percent, respectively). Lead study investigator Alison Stopeck, MD, of the University of Arizona Cancer Center, told reporters that these findings show that osteonecrosis of the jaw is not a class effect of bisphosphonates (like Zometa), but rather an effect of all drugs that inhibit osteoclasts, the cells that break down bone. 

Denosumab, a monoclonal antibody, is given as a subcutaneous injection and works by blocking a protein called RANK ligand, which tells the body to remove bone. Zometa, an intravenous bisphosphonate, uses a slightly different strategy—it attaches directly to the surface of bone to halt bone breakdown. 

Amgen, the maker of denosumab, plans to file the drug for approval in the first quarter of next year for the treatment of bone metastases, said Lisa Rooney, a spokesperson for the company. In addition to the study presented at the meeting, research demonstrating denosumab’s effectiveness in prostate cancer and other solid tumors will be part of the approval application, she said. 

This article is a part of CURE’s 2009 San Antonio Breast Cancer Symposium coverage. To read more articles from SABCS 2009, visit sabcs2009.curetoday.com.













Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
Related Articles
Angelina Jolie, Knowledge Is Not Enough
Two years ago, Angelina Jolie Pitt told the world that she held the BRCA1 mutation.
 Practicing Stress Management Improves Long-Term Mood, Quality of Life in Women with Breast Cancer
BY CHRISTINA IZZO
Results of a follow up study have shown that when women were taught stress management techniques early in their breast cancer treatment, their mood and quality of life continued to improve up to 15 years later.
Birthdays Mark Milestones
BY TERRY ARNOLD
Inflammatory breast cancer survivor, Terry Arnold, shares her story of diagnosis and survivorship.
Clinical Trial Seeks to Unravel Mystery of Chemobrain in Breast Cancer
BY CHRISTINA IZZO
A new study hopes to gain some clarity on what causes some breast cancer patients to feel “foggy” when receiving chemotherapy.
Cancer Survivorship Experts and Apple Unveil Mobile App to Accelerate Research
BY ELIZABETH WHITTINGTON
Cancer research groups, Apple and breast cancer organizations partner to accelerate survivorship research.
Related Videos
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
Medical Updates from the 32nd Annual Miami Breast Cancer Conference
The evolution of the treatment for hormone receptor-positive breast cancer was a hot topic for this year's Miami Breast Cancer Conference. Debu Tripathy, CURE's editor-in-chief and breast oncologist, reports from the meeting.
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$